A US Court of Appeals ruled in favor of AstraZeneca, Novo Nordisk, and Sanofi in a case over the 340B Drug Pricing Program. The court decided that the companies could not be held responsible to provide the discounts mandated by the program at an unlimited number of pharmacies serving under-insured, lower-income communities.
According to , “Under Section 340B, drug makers that take part in Medicare or Medicaid must offer their drugs at a steep discount for certain low-income patients. But in recent years hospitals have added an increasing number of pharmacies requiring 340B prices, forcing the market to balloon to 15% of US pharma sales in 2021, according to IQVIA.”
To read more, click here.
(Source: Endpoints News, January 30th, 2023)